clinical trial · NCT02480374
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer
Imunon·phase1·completed·n = 18
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerIMNN-001
brief summary
This dose escalation study will determine a maximum tolerated dose and/or optimal biological dose of GEN-1 for carboplatin/paclitaxel combination in newly diagnosed ovarian cancer.
started
Sep 1, 2015
primary completion
May 1, 2017
completion
May 1, 2017
last updated
Oct 2, 2024
official title
A Phase I Study of the Safety and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed with Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol